Recombinant Fusion Proteins
"Recombinant Fusion Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.
| Descriptor ID |
D011993
|
| MeSH Number(s) |
D12.776.828.300
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Recombinant Fusion Proteins".
Below are MeSH descriptors whose meaning is more specific than "Recombinant Fusion Proteins".
This graph shows the total number of publications written about "Recombinant Fusion Proteins" by people in this website by year, and whether "Recombinant Fusion Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 4 | 11 | 15 |
| 1996 | 3 | 15 | 18 |
| 1997 | 1 | 20 | 21 |
| 1998 | 2 | 15 | 17 |
| 1999 | 1 | 15 | 16 |
| 2000 | 0 | 20 | 20 |
| 2001 | 4 | 21 | 25 |
| 2002 | 5 | 20 | 25 |
| 2003 | 5 | 18 | 23 |
| 2004 | 5 | 21 | 26 |
| 2005 | 4 | 21 | 25 |
| 2006 | 2 | 15 | 17 |
| 2007 | 1 | 13 | 14 |
| 2008 | 1 | 11 | 12 |
| 2009 | 5 | 26 | 31 |
| 2010 | 3 | 14 | 17 |
| 2011 | 10 | 17 | 27 |
| 2012 | 3 | 9 | 12 |
| 2013 | 4 | 11 | 15 |
| 2014 | 4 | 13 | 17 |
| 2015 | 6 | 6 | 12 |
| 2016 | 2 | 9 | 11 |
| 2017 | 9 | 13 | 22 |
| 2018 | 4 | 5 | 9 |
| 2019 | 5 | 4 | 9 |
| 2020 | 10 | 2 | 12 |
| 2021 | 3 | 9 | 12 |
| 2022 | 1 | 11 | 12 |
| 2023 | 2 | 9 | 11 |
| 2024 | 3 | 4 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Recombinant Fusion Proteins" by people in Profiles.
-
Anti-CD8/IL-15 (N72D)/sushi fusion protein: A promising strategy for improvement of cancer immunotherapy. Cytokine. 2025 Jan; 185:156822.
-
Is luspatercept the new standard of care in transfusion-dependent low-risk myelodysplastic syndromes? Clin Adv Hematol Oncol. 2024 Oct; 22(8):367-369.
-
Suppression of matrigel-induced choroidal neovascularization by AAV delivery of a novel anti-Scg3 antibody. Gene Ther. 2024 Nov; 31(11-12):587-593.
-
Safety and efficacy of luspatercept for the treatment of anemia in?patients with myelofibrosis. Blood Adv. 2024 09 10; 8(17):4511-4522.
-
MERLIN: Two-Year Results of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid. Ophthalmology. 2025 Feb; 132(2):131-140.
-
Anti-VEGF Pharmaceutical Prior Authorization in Retina Practices. JAMA Ophthalmol. 2024 Aug 01; 142(8):716-721.
-
Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study. Haematologica. 2024 08 01; 109(8):2660-2664.
-
Biochemical Characterization and Application of Zearalenone Lactone Hydrolase Fused with a Multifunctional Short Peptide. J Agric Food Chem. 2024 Aug 14; 72(32):18146-18154.
-
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial. Lancet Haematol. 2024 Sep; 11(9):e646-e658.
-
Impact of COVID-19 on a real-world treat-and-extend regimen with aflibercept for neovascular age-related macular degeneration. Can J Ophthalmol. 2025 Feb; 60(1):e92-e99.